RNF217抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: HepG2 cell lysate, Primary antibody: P06724(RNF217 Antibody) at dilution 1/250, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

The RNF217 antibody is a research tool designed to detect and study the Ring Finger Protein 217 (RNF217), an E3 ubiquitin ligase involved in cellular processes such as protein degradation, lipid metabolism, and signaling regulation. RNF217 contains a conserved RING domain, enabling its role in ubiquitination—a post-translational modification that tags proteins for proteasomal degradation or functional modulation. It has garnered attention for its association with metabolic and cardiovascular diseases, particularly through its interaction with lipid-regulating pathways. Studies link RNF217 to cholesterol homeostasis by promoting the degradation of LDLR (low-density lipoprotein receptor), influencing plasma cholesterol levels and atherosclerosis development.

Additionally, RNF217 is implicated in cancer, where its dysregulation may affect tumor progression, apoptosis, and drug resistance. Its overexpression has been observed in certain malignancies, suggesting potential as a biomarker or therapeutic target. In neurological contexts, RNF217 interacts with proteins linked to neurodegenerative disorders like Alzheimer’s disease, though its precise role remains under investigation.

The RNF217 antibody is widely used in techniques such as Western blotting, immunohistochemistry, and immunoprecipitation to analyze protein expression, localization, and molecular interactions. Researchers utilize it to explore RNF217's physiological and pathological mechanisms, aiding in the development of targeted therapies for related diseases. Validation of antibody specificity remains critical, given the structural similarities among E3 ligases.